

Product Name: BPTES Revision Date: 01/10/2021 **Product Data Sheet**

BPTES

Cat. No.:	B6008
CAS No.:	3 <mark>140</mark> 45-39-1
Formula:	C24H24N6O2S3
M.Wt:	524.68
Synonyms:	
Target:	Others
Pathway:	Others
Storage:	Store at -20°C
	BIO

Solvent & Solubility

	insoluble in H2O; ins	insoluble in H2O; insoluble in EtOH; \geq 18 mg/mL in DMSO			
Preparing In Vitro Stock Solutions		Mass Solvent Concentration	1mg	5mg	10mg
	1 mM	1.9059 mL	9.5296 mL	19.0592 mL	
	<u>810</u>	5 mM	0.3812 mL	1.9059 mL	3.8118 mL
	PENE	10 mM	0.1906 mL	0.9530 mL	1.9059 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

GLS inhibitor

IC₅₀ & Target

In Vitro

Cell	Viability	Assa

Cell Viability Assay	and the second
Cell Line:	AML cells
Preparation method:	The solubility of this compound in DMSO is > 18 mg/mL. General tips for
	obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes
	and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
	below - 20 °C for several months.
Reacting conditions:	20 or 40 μM

09. X

1 | www.apexbt.com

	Applications:	After being expected to 20 JM PDTES for 4 days, all IDH1 mutant AML colle	
	Applications:	After being exposed to 20 µM BPTES for 4 days, all IDH1-mutant AML cells	
		were reduced approximately by 50%. The doses of 20 μM and 40 μM exhibited	
		similar effects. However, BPTES did not significantly affect the growth of wild	
		type AML cells. According to the mass spectrometry analysis, BPTES did not	
		significantly change α -KG or 2-HG levels in IDH-mutant or wild type AML cells.	
	Animal experiment	319	
	Animal models:	Mice harboring P493 tumor xenografts	
	Dosage form:	200 μg; i.p.; every 3 days for 10 <mark>days</mark>	
	Applications:	In mice harboring P493 tumor xenografts, BPTES reduced tumor growth by	
		approximately 50% over a 10-day treatment period. However, BPTES did not	
In Vivo Other notes:		inhibit the growth of P493 xenografts expressing wild type GLS or	
		BPTES-resistant mutant GLS K325A. According to the metabolic analysis of	
		P493 xenografts, BPTES treatment increased tumor glutamine levels and	
		decreased glutamate levels.	
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may	
	DE construction	slightly differ with the theoretical value. This is caused by an experimental	
	Contraction of the second	system error and it is normal.	

Product Citations

See more customer validations on www.apexbt.com.



[1]. Emadi A, Jun SA, Tsukamoto T, et al. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Experimental hematology, 2014, 42(4): 247-251.

APERBIO

[2]. Xiang Y, Stine ZE, Xia J, Lu Y, O'Connor RS, Altman BJ, Hsieh AL, Gouw AM, Thomas AG, Gao P, Sun L, Song L, Yan B, Slusher BS, Zhuo J, Ooi LL, Lee CG, Mancuso A, McCallion AS, Le A, Milone MC, Rayport S, Felsher DW, Dang CV. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest. 2015 Jun;125(6):2293-306.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt


2 | www.apexbt.com

of the product, follow the storage recommendations on the product data sheet.





www.apexbt.com







APERBIO







